Current Editions
A second non-ambulatory DMD patient has died in Sarepta’s ENVISION study of Elevidys
Editor's Commentary
BIO’s new board chair on MFN pricing, political realism, and why the industry can’t just say no anymore
Politics, Policy & Law
Industry enthusiastic about streamlining reviews, concerned the program could become politicized
Politics, Policy & Law
Verve takeout adds base editing platform with big CV market opportunities
Deals
Product Development
Scholar Rock shows 55% lean mass preservation for apitegromab vs. Zepbound in Phase II readout
ADA data show 11.5% placebo-adjusted weight loss at 12 weeks for eloralintide
Emerging Company Profile
SV Health, others back programs from Cardiff University in nine-digit series A
Data Byte
Four of the five are already approved in the U.S.
Finance
Plus: Venture rounds for Welsh start-up Draig, San Diego’s Actio
U.K. firm will steer portfolio toward returns for shareholders, while aiming to build new fund away from public markets
Management Tracks
Butte was chief data scientist for the University of California Health Care System
Biopharma Stock Performers
Use BioCentury's interactive dashboard to view top-performing biopharma stocks for the day and the week.
Product Development
Politics, Policy & Law
BioCentury ISSN 1097-7201